The First Hearing Loss Cure | FX-322 Update | Frequency Therapeutics

FX-322 is a new pharmaceutical research drug by Frequency Therapeutics aimed at finding a cure for hearing loss.

FX-322 is a new pharmaceutical research drug by Frequency Therapeutics aimed at finding a cure for hearing loss. This article will discuss updates in the drug’s development and its effectiveness in trials thus far, as well as its potential as a form of treatment for those with hearing loss or tinnitus.

Dr. Thompson explains FX-322 and its implications for tinnitus patients.

FX-322: Can It Cure Tinnitus?

FX-322 aims to cure hearing loss and tinnitus by naturally repairing or reversing damage caused by degenerative disease. This diagnosis is generally referred to as age-related or sensorineural hearing loss.

Phase 1b of the trial looked at patients with mild to moderately severe age-related hearing loss of ages 66 to 85. Another 1b trial looked at patients with severe hearing loss of ages 18 to 65. In an article from Otology & Neurotology published in February 2021, the researchers mention that these trials aimed at improving speech intelligibility in subjects with stable sensorineural hearing loss, the most common type of hearing loss, following an intratympanic dosing of FX-322, which means putting the drug through the eardrum and having it affect the inner hearing organ, known as the cochlea.

This study was mainly composed of guinea pigs—which are the most commonly tested animal in studies seeking to replicate the human cochlea—but also included some intratympanic dosing with humans. Most importantly, the study was a randomized, double-blind, placebo-controlled clinical trial in three different ENT clinics in the US. The individuals in the study were diagnosed with mild to moderately severe sensorineural hearing loss in one or both ears for more than six months, and six real patients were administered a dose of FX-322. Out of the six, four showed clinically significant improvements, meaning that their word recognition scores improved between 18% and 42%, as opposed to no significant changes observed in the placebo group. Thus, the conclusions of this study show that the delivery of FX-322 to the extended high-frequency region of the cochlea is well-tolerated and may enhance speech recognition performance in multiple subjects with stable chronic hearing loss.

Can Progenitor Cells Cure Hearing Loss or Tinnitus?

FX-322 is part of a new class of therapeutics designed to activate progenitor cells. Progenitor cells are similar to stem cells in that they are programmed to create specific cell types. These cells remain active and regenerate in some organs and tissues and become dormant in others. The research so far has shown some improvement in patients with age-related hearing loss who were administered FX-322.

If you have a similar condition, it is important to consider that if this drug got released and approved for some kinds of hearing loss or tinnitus, it would likely only be available to a very small subset of people. Further data and information would have to be collected before releasing the drug to more people. For this reason, even if FX-322 is proven effective, it will take years to actually be released to the general public. That said, this blog will continue to monitor relevant research and progress.

To learn what may help you manage your tinnitus, please download our free 10-page e-book, The Ultimate Guide to Tinnitus Relief. Dr. Thompson also offers online Tinnitus Retraining Therapy with Pure Tinnitus.

Dr. Ben Thompson, Au.D.

Dr. Ben Thompson, Au.D.

Dr. Ben Thompson is an audiologist in California and founder of Pure Tinnitus. Dr. Thompson has a comprehensive knowledge of tinnitus management. He completed his residency at University of California at San Francisco (UCSF) and is a past board member of the California Academy of Audiology. Via telehealth, Dr. Thompson provides services to patients with hearing loss and tinnitus.

You may also like